Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • JASN Podcasts
    • Article Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Editorial Fellowship
    • Editorial Fellowship Team
    • Editorial Fellowship Application Process
  • More
    • About JASN
    • Advertising
    • Alerts
    • Feedback
    • Impact Factor
    • Reprints
    • Subscriptions
  • ASN Kidney News
  • Other
    • ASN Publications
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • ASN Publications
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • JASN Podcasts
    • Article Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Editorial Fellowship
    • Editorial Fellowship Team
    • Editorial Fellowship Application Process
  • More
    • About JASN
    • Advertising
    • Alerts
    • Feedback
    • Impact Factor
    • Reprints
    • Subscriptions
  • ASN Kidney News
  • Follow JASN on Twitter
  • Visit ASN on Facebook
  • Follow JASN on RSS
  • Community Forum
UP FRONT MATTERSEditorials
You have accessRestricted Access

Stressed-out Podocytes in Diabetes?

Robert F. Spurney and Thomas M. Coffman
JASN November 2008, 19 (11) 2035-2037; DOI: https://doi.org/10.1681/ASN.2008090955
Robert F. Spurney
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas M. Coffman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • View PDF
Loading

Diabetic nephropathy is the most common cause of ESRD in the United States.1 Although current strategies can slow disease progression,2,3 development of renal failure requiring renal replacement therapy is a distressingly common outcome in patients with diabetes.1 As a result, much effort has been devoted to understanding the mechanisms that promote glomerular damage in diabetic kidney disease with the hope of identifying new therapeutic targets and strategies. In this issue of JASN, Zheng et al.4 report that the specific expression of the antioxidant protein metallothionein (MT) in podocytes reduces albuminuria, attenuates the loss of glomerular podocytes, and ameliorates glomerular injury in a mouse model of diabetes. These findings suggest diabetes enhances oxidative stress in podocytes, causing podocyte depletion and promoting the development of nephropathy.

In times past, the mesangial cell was a major focus of research into the molecular mechanisms of diabetic nephropathy. This emphasis was driven by clinical observations that accumulation of extracellular matrix in the mesangium is a characteristic pathologic finding in patients with diabetes. In addition, mesangial cells are relatively easy to isolate and study in culture; however, accumulating evidence suggests that glomerular podocytes also play a pivotal role in the pathogenesis of diabetic kidney disease.5 In this regard, foot process widening and loss of glomerular nephrin is observed early in the course of both experimental and human diabetic kidney disease.5,6 More recently, reduced podocyte number has been reported in humans with either type 1 or type 2 diabetic nephropathy.7–9 Podocytes are terminally differentiated cells with little potential for proliferation10,11 except in disease states such as HIV nephropathy12 and crescentic glomerulonephritis,13 in which a maladaptive proliferation may occur. Thus, podocytes that are lost from the glomerulus cannot be effectively replaced, and sufficient loss of these glomerular epithelial cells may lead to instability of the tuft and glomerulosclerosis.11 Several lines of evidence suggest podocyte loss contributes to progressive deterioration in kidney function in patients with diabetic nephropathy.5,7–9 For example, reduction of podocyte number is a strong predictor of progressive renal disease in Pima Indians with type 2 diabetes and microalbuminuria.7 Similarly, albumin excretion rates are negatively correlated with podocyte number in patients with proteinuria and type 1 diabetes.8 Finally, the density of glomerular podocytes is reduced to a greater extent in patients with diabetes and overt proteinuria compared with patients with microalbuminuria.9

Although the precise mechanisms causing loss of podocytes from the glomerulus in diabetic nephropathy are not known with certainty, both apoptosis and detachment likely play a role.5 Indeed, excretion of urinary podocytes is detected in both humans and rodents with diabetic nephropathy,14,15 and the extent of podocyturia correlates with disease activity.15 In rodent models, viable podocytes can be recovered from urine and cultured ex vivo15 indicating that podocytes may detach without undergoing apoptosis. Other studies suggested a role for podocyte apoptosis as a mechanism of podocyte loss in diabetic nephropathy.16,17 For example, Böttinger and co-workers16 found that podocyte apoptosis coincided with the onset of albuminuria and preceded detectable loss of podocytes in two different mouse models of diabetes. Moreover, increased ambient glucose concentrations stimulated the generation of reactive oxygen species (ROS) in cultured podocytes, inducing apoptosis.16 Podocyte apoptosis has also been documented early in the course of kidney disease in patients with type 2 diabetes.17

A role for exaggerated ROS generation has also been demonstrated in a number of diabetic complications,18 and several reports suggested decreasing oxidative stress can protect against kidney injury in diabetic nephropathy.16,19,20 Long-term treatment with an NADPH oxidase inhibitor prevented podocyte apoptosis and ameliorated glomerular injury in rodent models of type 1 and type 2 diabetes.16 Moreover, a ubiquitously expressed superoxide dismutase 1 transgene reduced kidney injury in streptozotocin-treated19 and db/db mice.20 Although these studies support a role for ROS in diabetic nephropathy, they do not identify the key cellular sites where ROS must be neutralized to ameliorate renal disease. This is the issue addressed by Zheng et al.,4 who tested whether providing antioxidant protection to the podocyte alone would confer protection from diabetic nephropathy. To this end, the authors generated transgenic mouse lines overexpressing the antioxidant protein MT in glomerular podocytes under control of the mouse nephrin promoter. Two founder lines were established with different levels of MT expression, six- or 18-fold higher than normal. These MT-overexpressing mice were crossed with the OVE26 TG line, a mouse model of severe, early-onset type 1 diabetes.21 Overexpression of MT in podocytes did not affect the basic metabolic characteristics of diabetes in OVE26 TG mice. Albuminuria, however, was reduced in both transgenic lines, although the reduction in albumin excretion was most marked in the founder line with lowest level of MT expression. Likewise, enhanced expression of MT in podocytes reduced apoptosis, preserved podocyte numbers, and prevented podocyte effacement. This was associated with attenuated glomerular pathology and reductions of glomerular and mesangial volumes. The authors, therefore, concluded that reducing oxidative stress in podocytes by overexpression of MT is sufficient to ameliorate diabetic kidney disease, providing further support for a central role of the podocyte in this disorder.

Although the studies by Zheng et al. advance our understanding of the pathogenesis of diabetic nephropathy, several caveats should be considered. First, MT is a multifunctional protein.22,23 In addition to its antioxidant properties, cysteine-rich MT binds heavy metals and may act as a reservoir for essential metals such as zinc.22,23 As a result, MT may modulate the activity of various transcription factors by either donating or chelating zinc that may be required for their biologic activity.22,23 Indeed, MT levels are altered in human cancer cell lines, and this may play a role in protecting against cellular apoptosis,22,23 in part by chelating zinc and decreasing the activity of the zinc-dependent tumor suppressor protein p53.23 The magnitude of ROS generation was not measured in the studies by Zheng et al.; therefore, the relative contribution of antioxidant actions versus other properties of MT in the observed renal protection cannot be specifically distinguished. In the future, it would be important to document directly enhanced oxidative stress in diabetic podocytes in vivo and to determine whether the extent of kidney protection can be correlated with abrogation of ROS generation in podocytes.

Although the strategy of specific overexpression of transgene-encoded proteins in podocytes has been widely used in the field, this approach can also have unexpected consequences, confounding interpretation of such experiments. For example, diabetes-associated albuminuria was attenuated to a greater extent in the transgenic line with lower levels of MT transgene expression (six-fold above normal) compared with the higher expressing line (18-fold above normal). Moreover, preliminary studies reported by the authors suggested that further increasing podocyte MT levels may cause spontaneous albuminuria. One wonders whether the failure of even the low-expressing MT transgene to protect against albuminuria over the long term may relate to nonspecific, seemingly detrimental consequences of transgene overexpression. Alternatively, the observed differences in the phenotypes of the two transgenic mouse lines might be a consequence of off-target effects related to differences in integration sites. Conditional knockout of endogenous antioxidant proteins specifically in podocytes would be an alternative approach to explore this issue further that potentially avoids some of the pitfalls inherent to overexpression studies.

In summary, the work by Zheng et al.4 provide suggestive evidence that, similar to other target tissues such as the vasculature,18 oxidative stress within the podocyte contributes to the pathogenesis of kidney damage in diabetes. A number of interesting questions remain. What is the extent of ROS generation in podocytes during diabetes? Are there biomarkers that can be used to monitor oxidative stress of the glomerulus in patients? What is the mechanism driving ROS generation in podocytes in diabetes? Can this be modulated in vivo? Answering these questions and developing therapeutic strategies that assuage podocyte stress may be useful in the future for preventing disease progression in diabetic nephropathy.

DISCLOSURES

None.

Footnotes

  • Published online ahead of print. Publication date available at www.jasn.org.

  • See related article, “Podocyte-Specific Overexpression of the Antioxidant Metallothionein Reduces Diabetic Nephropathy,” on pages 2077–2085.

  • © 2008 American Society of Nephrology

REFERENCES

  1. ↵
    USRDS: The United States Renal Data System. Am J Kidney Dis 42 [Suppl 1]: 1 –230, 2003
    OpenUrlPubMed
  2. ↵
    Lewis EJ, Hunsicker LG, Clarke WR, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329 : 1456 –1462, 1993
    OpenUrlCrossRefPubMed
  3. ↵
    Brenner BM, Cooper ME, Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 : 861 –869, 2001
    OpenUrlCrossRefPubMed
  4. ↵
    Zheng S, Carlson EC, Yang L, Kralik PM, Huang Y, Epstein PN: Podocyte-specific overexpression of the antioxidant metallothionein reduces diabetic nephropathy. J Am Soc Nephrol 19 : 2077 –2085, 2008
    OpenUrlAbstract/FREE Full Text
  5. ↵
    Wolf G, Chen S, Ziyadeh FN: From the periphery of the glomerular capillary wall toward the center of disease: Podocyte injury comes of age in diabetic nephropathy. Diabetes 54 : 1626 –1634, 2005
    OpenUrlAbstract/FREE Full Text
  6. ↵
    Jefferson JA, Shankland SU, Pichler RH: Proteinuria in diabetic kidney disease: A mechanistic viewpoint. Kidney Int 74 : 22 –36, 2008
    OpenUrlCrossRefPubMed
  7. ↵
    Meyer TW, Bennett PH, Nelson RG: Podocyte number predicts long-term urinary albumin excretion in Pima Indians with type II diabetes and microalbuminuria. Diabetologia 42 : 1341 –1344, 1999
    OpenUrlCrossRefPubMed
  8. ↵
    White KE, Bilous R, Marshall SM, Nahas ME, Remuzzi G, Pieras G, De Cosmo S, Viberti G: Podocyte number in normotensive type 1 diabetic patients with albuminuria. Diabetes 51 : 3083 –3089, 2002
    OpenUrlAbstract/FREE Full Text
  9. ↵
    Dalla Vestra M, Masiero A, Roiter AM, Saller A, Crepaldi G, Fioretto P: Is podocyte injury relevant in diabetic nephropathy? Studies in patients with type 2 diabetes. Diabetes 52 : 1031 –1035, 2003
    OpenUrlAbstract/FREE Full Text
  10. ↵
    Kritz W, Gretz N, Lemley KV: Progression of glomerular diseases: Is the podocyte the culprit? Kidney Int 54 : 687 –697, 1998
    OpenUrlCrossRefPubMed
  11. ↵
    Wiggins RC: The spectrum of podocytopathies: A unifying view of glomerular diseases. Kidney Int 71 : 1205 –1214, 2007
    OpenUrlCrossRefPubMed
  12. ↵
    He JC, Husain M, Sunamoto M, D'Agati VD, Klotman ME, Iyengar R, Klotman PE: Nef stimulates proliferation of glomerular podocytes through activation of Src-dependent Stat3 and MAPK1,2 pathways. J Clin Invest 114 : 643 –651, 2004
    OpenUrlCrossRefPubMed
  13. ↵
    Ding M, Cui S, Li C, Jothy S, Haase V, Steer BM, Marsden PA, Pippin J, Shankland S, Rastaldi MP, Cohen CD, Kretzler M, Quaggin SE: Loss of the tumor suppressor Vhlh leads to upregulation of Cxcr4 and rapidly progressive glomerulonephritis in mice. Nat Med 12 : 1081 –1087, 2006
    OpenUrlCrossRefPubMed
  14. ↵
    Nakamura T, Ushiyama C, Suzuki S, Hara M, Shimada N, Ebihara I, Koide H: Urinary excretion of podocytes in patients with diabetic nephropathy. Nephrol Dial Transplant 15 : 1379 –1383, 2000
    OpenUrlCrossRefPubMed
  15. ↵
    Petermann AT, Pippin J, Krofft R, Bionski M, Griffin S, Durvasula R, Shankland SJ: Viable podocytes detach in experimental diabetic nephropathy: Potential mechanisms underlying glomerulosclerosis. Nephron Exp Nephrol 98 : e114 –e123, 2004
    OpenUrlCrossRefPubMed
  16. ↵
    Susztak K, Raff AC, Schiffer M, Böttinger EP: Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 55 : 225 –233, 2006
    OpenUrlAbstract/FREE Full Text
  17. ↵
    Verzola D, Bandolfo MT, Ferrario F, Rastaldi MP, Villaggio B, Gianiorio F, Giannoni M, Rimoldi L, Lauria F, Miji M, Deferrari G, Garibotto G: Apoptosis in the kidneys of patients with type II diabetic nephropathy. Kidney Int 72 : 1262 –1272, 2007
    OpenUrlCrossRefPubMed
  18. ↵
    Kuroki T, Isshiki K, King GL: Oxidative stress: The lead or supporting actor in the pathogenesis of diabetic complications. J Am Soc Nephrol 14 [Suppl 3]: S216 –S220, 2003
    OpenUrlFREE Full Text
  19. ↵
    Craven P, Melhem M, Phillips SL, DeRubertis FR: Overexpression of Cu2+/Zn2+ superoxide dismutase protects against early diabetic glomerular injury in transgenic mice. Diabetes 50 : 2114 –2125, 2001
    OpenUrlAbstract/FREE Full Text
  20. ↵
    DeRubertis FR, Craven P, Melhem, Salah EM: Attenuation of renal injury in db/db mice overexpression superoxide dismutase: Evidence for reduced superoxide-nitric oxide interaction. Diabetes 53 : 762 –768, 2004
    OpenUrlAbstract/FREE Full Text
  21. ↵
    Zheng S, Noonan WT, Metreveli NS, Coventry S, Kralik PM, Carlson EC, Epstein PN: Development of late-stage diabetic nephropathy in OVE26 diabetic mice. Diabetes 53 : 3248 –3257, 2004
    OpenUrlAbstract/FREE Full Text
  22. ↵
    Cherian MG, Jayasurya A, Bay BH: Metallothioneins in human tumors and potential roles in carcinogenesis. Mutation Res 533 : 201 –209, 2003
    OpenUrlPubMed
  23. ↵
    Theocharis SE, Margeli AP, Klijanienko JT, Kouraklis GP: Metallothionen expression in human neoplasia. Histopathology 45 : 103 –118, 2004
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Journal of the American Society of Nephrology: 19 (11)
Journal of the American Society of Nephrology
Vol. 19, Issue 11
November 2008
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in JASN.
Enter multiple addresses on separate lines or separate them with commas.
Stressed-out Podocytes in Diabetes?
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Stressed-out Podocytes in Diabetes?
Robert F. Spurney, Thomas M. Coffman
JASN Nov 2008, 19 (11) 2035-2037; DOI: 10.1681/ASN.2008090955

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Stressed-out Podocytes in Diabetes?
Robert F. Spurney, Thomas M. Coffman
JASN Nov 2008, 19 (11) 2035-2037; DOI: 10.1681/ASN.2008090955
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • DISCLOSURES
    • Footnotes
    • REFERENCES
  • Info & Metrics
  • View PDF

More in this TOC Section

UP FRONT MATTERS

  • Predicting Future Outcomes from Kidney Biopsies with MCD/FSGS Lesions: Opportunities and Limitations
  • Kidney Health Disparities: The Goal is Elimination
  • Autoimmune Renal Calcium and Magnesium Wasting
Show more UP FRONT MATTERS

Editorials

  • A Novel Pathological Mechanism of Tertiary Lymphoid Structure Formation in the Renal Pelvis
  • Disarming the Old Foe. Restoring T-Cell Immune Function with mTor-Inhibitors to Tackle Cytomegalovirus Infection
  • Genome-wide Admixture Mapping of eGFR and CKD Identify European and African Ancestry-of-Origin Loci in US Hispanics/Latinos
Show more Editorials

Cited By...

  • Absence of miR-146a in Podocytes Increases Risk of Diabetic Glomerulopathy via Up-regulation of ErbB4 and Notch-1
  • Genetic and Pharmacologic Targeting of Glycogen Synthase Kinase 3{beta} Reinforces the Nrf2 Antioxidant Defense against Podocytopathy
  • Thioredoxin-Interacting Protein Deficiency Protects against Diabetic Nephropathy
  • Google Scholar

Similar Articles

Related Articles

  • Podocyte-Specific Overexpression of the Antioxidant Metallothionein Reduces Diabetic Nephropathy
  • PubMed
  • Google Scholar

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Annual Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Author Resources
  • Editorial Fellowship Program
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • JASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About JASN
  • JASN Email Alerts
  • JASN Key Impact Information
  • JASN Podcasts
  • JASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe to ASN Journals
  • Wolters Kluwer Partnership

© 2022 American Society of Nephrology

Print ISSN - 1046-6673 Online ISSN - 1533-3450

Powered by HighWire